Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of GW117 ODT in Healthy Volunteers
NCT06964711Phase 1Completed
- Sponsor
- Beijing Greatway Pharmaceutical Technology Co., Ltd.
- Start
- Jul 2021
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in major depressive disorder (MDD) comparing GW117 ODT with Placebo (2 arms). Primary endpoint: Percentage of participants with at least one safety event at Day 9. Started Jul 2021; status: completed.
02
Drugs
GW117
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT06964711.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06964711.